fda category 2 bulk drug substances list bpc-157 has removed certain that were placed on the two and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of bpc-157 regulation fda fda bpc-157

People with sleep disturbances, fatigue, or slow healing

This is erroneous hyperbole

SS-31 + MOTS-c + NAD+ blend: May support cellular energy production, mitochondrial function, and overall recovery during high training loads, particularly where fatigue is a limiting factor

Side Effects & Safety No lethal dose found -- toxicology studies couldn't establish an LD50 (Sikiric et al., 2006) No organ toxicity in chronic dosing No hormonal effects -- doesn't affect testosterone, estrogen, cortisol, or GH Mild nausea -- mostly with oral dosing Brief lightheadedness -- occasionally after injection Injection site redness -- standard for SC peptides Angiogenesis concern -- promotes new blood vessel growth, which raises a theoretical question about existing tumors

FDA warning letters that mention BPC-157 I found three FDA warning letters mentioning this peptide

Pentadecapeptide BPC 157 and the central nervous system